Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform.
But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes. Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.
“Our position is that more supply, especially at a reasonable price, is needed right now, not less,” Noom CEO Geoff Cook told CNBC in an interview.
Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient’s appetite and regulate their blood sugar. The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.
Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.
Cook said consumers will pay $149 for their first month in Noom’s program and $279 for the following months as the dose of their medication increases.
The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency has urged consumers to take the approved, branded GLP-1 medications when they are available. However, the FDA does inspect some outsourcing facilities that compound drugs, according to its website.
Noom said it is working with an FDA-regulated 503B compounding pharmacy to provide its medication for its new program, which is called Noom GLP-1 RX.
“The drug manufacturer we’re working with generates 20 generic medications, epinephrine being one of them — a lifesaving medication that’s available in hospitals all across the United States,” Dr. Adonis Saremi, chief medical officer of Noom, told CNBC in an interview. “So we’re really confident and happy with our vetting process.”
The company said ithas also introduced a way for participants to taper off the compounded treatment if they would like to stop taking it. GLP-1s are intended for long-term use, which means some patients may end up taking them indefinitely.
Cook said Noom has seen both anecdotal and real-world evidence that patients are able to maintain weight loss after they stop taking the drugs. Six out of seven patients are off GLP-1s by the two-year mark anyway, he said.
“It’s prescribed by the doctor, the person takes their medicine, they lose weight, but then life happens,” Cook said. “They eventually stop taking the medication, or their insurance stops covering it, they’ll change a job [so] it’s no longer covered.”
Cook said not everyone will be able to taper off the medication, so some people will likely end up taking it indefinitely. The company will provide a free year of Noom or “substantial medication discounts” to anyone who regains the weight within 18 months after following its program for a year, it said in a release.
Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website. Noom said one of its contracted, obesity-trained doctors will review the intake form and decide if the compounded medication is appropriate for that patient. If so, the drugs will arrive at their door within a week, Noom said.
Participants will learn how to inject their medication, and they can use a chat feature to talk one-on-one with a coach and their Noom clinician, the company said. They’ll also have access to a range of psychology-based programming and tools to help keep them from losing muscle mass, such as features for tracking protein intake and engaging in resistance training, Noom said.
And if users decide they are ready to move off the medication, they can chat with their clinician or tap “initiate taper” in their settings, Noom said.
“I think there’s a lot of folks who don’t want to be on a medication for the rest of their lives, and in any event, people aren’t doing that in the real world,” Cook said. “Our goal is just not to sell more medications. It’s to drive sustained weight loss outcomes.”
Amazon on Friday announced it would invest an additional $4 billion in Anthropic, the artificial intelligence startup founded by ex-OpenAI research executives.
The new funding brings the tech giant’s total investment to $8 billion, though Amazon will retain its position as a minority investor, according to Anthropic, the San Francisco-based company behind the Claude chatbot and AI model.
Amazon Web Services will also become Anthropic’s “primary cloud and training partner,” according to a blog post. From now on, Anthropic will use AWS Trainium and Inferentia chips to train and deploy its largest AI models.
Anthropic is the company behind Claude — one of the chatbots that, like OpenAI’s ChatGPT and Google’s Gemini, has exploded in popularity. Startups like Anthropic and OpenAI, alongside tech giants such as Google, Amazon, Microsoft and Meta, are all part of a generative AI arms race to ensure they don’t fall behind in a market predicted to top $1 trillion in revenue within a decade. Some, like Microsoft and Amazon, are backing generative AI startups with hefty investments as well as working on in-house generative AI.
The partnership announced Friday will also allow AWS customers “early access” to an Anthropic feature: the ability for an AWS customer to do fine-tuning with their own data on Anthropic’s Claude. It’s a unique benefit for AWS customers, according to a company blog post.
In March, Amazon’s $2.75 billion investment in Anthropic was the company’s largest outside investment in its three-decade history. The companies announced an initial $1.25 billion investment in September 2023.
Amazon does not have a seat on Anthropic’s board.
News of Amazon’s additional investment comes one month after Anthropic announced a significant milestone for the company: AI agents that can use a computer to complete complex tasks like a human would.
Anthropic’s new Computer Use capability, part of its two newest AI models, allows its tech to interpret what’s on a computer screen, select buttons, enter text, navigate websites and execute tasks through any software and real-time internet browsing.
The tool can “use computers in basically the same way that we do,” Jared Kaplan, Anthropic’s chief science officer, told CNBC in an interview last month, adding it can do tasks with “tens or even hundreds of steps.”
Amazon had early access to the tool, Anthropic told CNBC at the time, and early customers and beta testers included Asana, Canva and Notion. The company had been working on the tool since early this year, according to Kaplan.
In September, Anthropic rolled out Claude Enterprise, its biggest new product since its chatbot’s debut, designed for businesses looking to integrate Anthropic’s AI. In June, the company debuted its more powerful AI model, Claude 3.5 Sonnet, and in May, it rolled out its “Team” plan for smaller businesses.
Last year, Google committed to invest $2 billion in Anthropic, after previously confirming it had taken a 10% stake in the startup alongside a large cloud contract between the two companies.
LONDON — Apple and Google could face a competition investigation into their dominance of mobile web browsers and apps in the U.K.
The U.K.’s Competition and Markets Authority issued a report Friday with a provisional decision from an independent inquiry group tasked by the regulator with carrying out an in-depth review of the mobile browser markets.
In the report, the group recommended that the CMA investigates Apple and Google’s activities in mobile ecosystems under the new Digital Markets, Competition and Consumers Act (DMCC), a new U.K. law coming into force next year which seeks to prevent anti-competitive behavior in digital markets.
The DMCC is akin to the Digital Markets Act in the European Union. It gives the CMA the ability to designate firms as having “Strategic Market Status” (SMS) — which means they have a significant amount of market power in a certain digital business.
Under the rules, the CMA can impose major behavioral changes on firms that have SMS status, including ending “self-preferencing” of their own services, requiring interoperability — essentially allowing one piece of software to work with another smoothly — and banning anti-competitive behavior.
The CMA is required to undertake a formal investigation to give a firm SMS status.
For Apple specifically, the CMA inquiry group said it was concerned the tech giant’s App Store rules “restrict other competitors from being able to deliver new, innovative features that could benefit consumers” — for example, faster webpage loading on iPhone apps.
It added many smaller U.K. developers said they would like to use “progressive” web apps — which allow firms to offer apps outside of an app store — but that this technology “is not able to fully take off on iOS devices.”
The group also said it found a revenue-sharing agreement between Google and Apple to make Google the default search engine on iPhone “significantly reduces their financial incentives to compete in mobile browsers on iOS.”
“Markets work best when rival businesses are able to develop and bring innovative options to consumers,” Margot Daly, chair of the CMA’s independent inquiry group, said in a statement, adding that “competition between different mobile browsers is not working well and this is holding back innovation in the U.K.”
Apple said in a statement that it disagreed with the findings of the report and that it was concerned market interventions imposed under the DMCC “would undermine user privacy and hinder our ability to make the kind of technology that sets Apple apart.”
“Apple believes in thriving and dynamic markets where innovation can flourish. We face competition in every segment and jurisdiction where we operate, and our focus is always the trust of our users” an Apple spokesperson told CNBC via email.
Google was not immediately available for comment when contacted by CNBC.
The CMA group had also looked into restrictions on the distribution of gaming services on Apple’s mobile app distribution platform. However, it’s now decided to drop this element of the investigation following a decision by the U.S. tech giant to allow cloud gaming services on App Store.
The regulator said interested parties have until Dec. 13 to share comments on its provisional findings. It expects to make a final decision in March 2025.
An iPhone 16 signage is seen on the window at the Fifth Avenue Apple Store on new products launch day on September 20, 2024 in New York City.
Michael M. Santiago | Getty Images News | Getty Images
The Indonesian government expects Apple to increase its proposed $100 million investment into the country, according to state media, as the iPhone maker seeks clearance from Jakarta to sell its latest phones.
The American tech giant’s latest smartphone model doesn’t meet Indonesia’s 40% domestic content requirements for smartphones and tablets and hasn’t been granted clearance to be sold in the country.
The purpose of the ban is to protect local industry and jobs, with officials asking Apple to increase its investments and commitments to the economy in order to gain greater access.
According to a report from Indonesian state media, the country’s Ministry of Industry met with representatives from Apple on Thursday regarding its proposal to invest $100 million over two years.
The funds would go toward a research and development center program and professional development academy in the country, as per the report.
The company also plans to produce accessory product components, specifically mesh for Apple’s AirPods Max, starting in July 2025, it added.
Apple didn’t immediately respond to a request for comment from CNBC.
While the new offer is 10 times larger than a proposal that was reported earlier, the government is still striving to sweeten the deal to get a “fair” commitment.
“From the government’s perspective, of course, we want this investment to be larger,” industry ministry spokesperson Febri Hendri Antoni Arif told state media on Thursday.
He said that a larger investment would help the development of Indonesia’s manufacturing sector, adding that its domestic industry was capable of supporting production of Apple devices such as chargers and accessories.
While Indonesia represents a small market for Apple, it also offers growth opportunities as it has the world’s fourth-largest population, according to Le Xuan Chiew, a Canalys analyst focusing on Apple strategy research.
“Its young, tech-savvy population with growing digital literacy aligns with Apple’s strategy to expand [global sales],” he said, noting that it also offers potential for manufacturing and assembly that supports Apple’s efforts to diversify its supply chain.
Success in this market requires a long-term approach, and Apple’s investment offer demonstrates a commitment to complying with local regulations and paving the way for future growth, he added.
